ClinConnect ClinConnect Logo
Search / Trial NCT06455098

A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF)

Launched by BIOSENSE WEBSTER, INC. · Jun 7, 2024

Trial Information

Current as of June 04, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment method for a heart condition called paroxysmal atrial fibrillation (PAF), which causes an irregular heartbeat and can lead to poor blood flow. Researchers want to find out how safe and effective the BWI OMNYPULSE™ pulsed field ablation (PFA) platform is for isolating certain heart veins over a period of 12 months. The trial is currently looking for participants aged 65 to 74 who have experienced at least two episodes of symptomatic PAF in the last six months and have not found relief with at least one antiarrhythmic medication.

If you or a loved one are interested in participating, you should be willing to provide consent and follow the testing requirements throughout the study. However, certain conditions might make you ineligible, such as previous surgeries for AF, severe heart issues, or specific medical problems that could complicate the treatment. Participants can expect regular check-ups and monitoring to assess the safety and effectiveness of this new treatment approach.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • * Diagnosed with symptomatic paroxysmal AF with:
  • 1. At least two symptomatic AF episodes within last six months from enrollment
  • 2. At least one electrocardiographically documented AF episode within twelve months prior to enrollment
  • Failed at least one Class I or Class III antiarrhythmic drug
  • Willing and capable to provide consent
  • Able and willing to comply with all pre-, post- and follow-up testing and requirements
  • Exclusion Criteria:
  • Previously diagnosed with persistent AF (greater than \[\>\] 7 days in duration)
  • AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  • Previous surgical or catheter ablation for AF
  • Patients known to require ablation outside the PV ostia and outside the CTI region.
  • Documented severe dilatation of the left atrium (LAD\>50 mm) antero-posterior diameter on imaging within 6 months prior to enrollment
  • Documented left atrium (LA) thrombus by imaging within 48 hours of the procedure
  • Documented severely compromised left ventricular ejection fraction (LVEF \<40%) by imaging within 6 months prior to enrollment
  • Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
  • History of blood clotting, bleeding abnormalities or contraindication to anticoagulation (heparin, warfarin, or dabigatran)
  • Documented thromboembolic event (including transient ischemic attack or TIA) within the past 6 months
  • Previous Percutaneous Coronary Intervention (PCI)/ myocardial infarction \[MI\] within the past 2 months
  • Coronary Artery Bypass Grafting (CABG) surgery within the past 6 months
  • Valvular cardiac surgical/percutaneous procedure
  • Unstable angina within 6 months
  • Anticipated cardiac transplantation, cardiac surgery, or other major surgery within the next 12 months
  • Significant pulmonary disease or any other disease or malfunction of the lungs or respiratory system that produces severe chronic symptoms
  • Significant congenital anomaly or medical problem that in the opinion of the investigator would preclude enrollment in this study
  • Prior diagnosis of pulmonary vein stenosis
  • Pre-existing hemi diaphragmatic paralysis
  • Acute illness, active systemic infection, or sepsis
  • Presence of intracardiac thrombus, myxoma, tumor, interatrial baffle or patch or other abnormality that precludes catheter introduction or manipulation
  • Severe mitral regurgitation
  • Presence of an implanted pacemaker or Implantable Cardioverter-Defibrillator (ICD) or other implanted metal cardiac device (other than coronary stents) that may interfere with the PF energy field)
  • Presence of a condition that precludes vascular access
  • Current enrollment in an investigational study evaluating another device or drug
  • Women who are pregnant (as evidenced by pregnancy test if pre-menopausal), lactating, or who are of child-bearing age and plan on becoming pregnant during the course of the clinical investigation
  • Life expectancy less than 12 months
  • Presenting contra-indications for the devices used in the study, as indicated in the respective Instructions for Use (IFU)

About Biosense Webster, Inc.

Biosense Webster, Inc., a subsidiary of Johnson & Johnson, is a leading innovator in the field of electrophysiology, specializing in advanced diagnostic and therapeutic solutions for cardiac arrhythmias. The company is dedicated to improving patient outcomes through cutting-edge technologies, including mapping systems and catheter-based therapies. With a robust commitment to clinical research and development, Biosense Webster actively sponsors clinical trials aimed at enhancing the understanding and treatment of heart rhythm disorders, ensuring that healthcare professionals have access to the most effective tools for patient care.

Locations

New York, New York, United States

Boston, Massachusetts, United States

Boston, Massachusetts, United States

Norfolk, Virginia, United States

Savannah, Georgia, United States

Cleveland, Ohio, United States

Hartford, Connecticut, United States

Morristown, New Jersey, United States

Aurora, Colorado, United States

Richmond, Virginia, United States

San Diego, California, United States

Loma Linda, California, United States

Houston, Texas, United States

Atlanta, Georgia, United States

Atlanta, Georgia, United States

Murray, Utah, United States

Baltimore, Maryland, United States

Albuquerque, New Mexico, United States

Newport Beach, California, United States

Philadelphia, Pennsylvania, United States

Adelaide, , Australia

Boston, Massachusetts, United States

York, Pennsylvania, United States

New York, New York, United States

Bronx, New York, United States

Austin, Texas, United States

Atlanta, Georgia, United States

Roslyn, New York, United States

Royal Oak, Michigan, United States

Phoenix, Arizona, United States

Burlingame, California, United States

Jacksonville, Florida, United States

Evanston, Illinois, United States

Orlando, Florida, United States

Jacksonville, Florida, United States

Raleigh, North Carolina, United States

Minneapolis, Minnesota, United States

San Francisco, California, United States

Miami, Florida, United States

Garran, , Australia

Santa Monica, California, United States

La Jolla, California, United States

Larkspur, California, United States

Naples, Florida, United States

New York, New York, United States

Falls Church, Virginia, United States

Glenview, Illinois, United States

Parkville, , Australia

Patients applied

0 patients applied

Trial Officials

Biosense Webster, Inc. Clinical Trial

Study Director

Biosense Webster, Inc.

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported